WGA Rescources

Abstract #108419 Published in IGR 23-4

Matrix metalloproteinase-3 (MMP-3)-mediated gene therapy for glaucoma

O'Callaghan J; Delaney C; O'Connor M; van Batenburg-Sherwood J; van Batenburg-Sherwood J; Schicht M; Lütjen-Drecoll E; Hudson N; Ni Dhubhghaill S; Humphries P; Stanley C; Keravala A; Chalberg T; Lawrence MS; Campbell M
Science advances 2023; 9: eadf6537

See also comment(s) by Makoto Aihara

Approximately 80 million people globally are affected by glaucoma, with a projected increase to over 110 million by 2040. Substantial issues surrounding patient compliance remain with topical eye drops, and up to 10% of patients become treatment resistant, putting them at risk of permanent vision loss. The major risk factor for glaucoma is elevated intraocular pressure, which is regulated by the balance between the secretion of aqueous humor and the resistance to its flow across the conventional outflow pathway. Here, we show that adeno-associated virus 9 (AAV9)-mediated expression of matrix metalloproteinase-3 (MMP-3) can increase outflow in two murine models of glaucoma and in nonhuman primates. We show that long-term AAV9 transduction of the corneal endothelium in the nonhuman primate is safe and well tolerated. Last, MMP-3 increases outflow in donor human eyes. Collectively, our data suggest that glaucoma can be readily treated with gene therapy-based methods, paving the way for deployment in clinical trials.

Smurfit Institute of Genetics, Trinity College Dublin, Dublin 2, Ireland.

Full article


15 Miscellaneous

Issue 23-4

Change Issue


WGA Rescources